Navigation Links
New phase II study supports potential of gs-9450 as new treatment option for steatohepatitis
Date:4/16/2010

Vienna, Austria, Thursday 15 April: Results from a multinational phase II study presented today at the International Liver CongressTM 2010 have shown that treatment with the caspase inhibitor GS-9450 can reduce markers of liver damage in patients with non-alcoholic steatohepatitis (NASH the most serious form of non-alcoholic liver disease) as demonstrated by reduced levels of alanine (ALT) and aspartate aminotransferases (AST), hepatic enzymes that indicate cell damage.

GS-9450, a potent inhibitor of caspases-8, -9 and -1, the intra-cellular proteins that initiate programmed cell death (or cell suicide, also known as apoptosis) in damaged cells, is a potential new treatment option for patients with NASH a disease characterised by fat build-up in liver cells with subsequent inflammation resulting in accumulation of scar tissue (fibrosis), cirrhosis and eventual liver failure.

Professor Fabio Marra of the EASL scientific committee commented: "It is encouraging to see that GS-9450-associated reduction of apoptosis and cell damage seen in animal models has translated to a significant patient population, and seems to be consistent with a good tolerability profile in patients from a variety of countries. Further studies are needed to evaluate the action of this therapy on histology and to confirm the drug's efficacy and safety in larger patient populations."

In this double-blind, parallel-group study, patients (n=124, principally male, mean age 45 years, with Body Mass Index (BMI) of >30kg/m2) with biopsy-proven NASH were randomised to receive 1, 5, 10 or 40mg GS-9450 or placebo once daily for 4 weeks. After 4 weeks on treatment, patients in the 40mg treatment group experienced the greatest reduction in ALT and AST levels.

At week four, linear regression of ALT versus GS-9450 dose was highly significant (p<0.0001) with 35% achieving ALT levels within the normal range (7-56 U/L ) compared to 0% at study baseline, and 48% achiev
'/>"/>

Contact: Isabelle Scali
media.easl2010@cohnwolfe.com
44-771-743-5103
European Association for the Study of the Liver
Source:Eurekalert

0

GOOD

Page: 1 2

Related medicine news :

1. NASA selects DNA Medicine Institutes Nanoscale Diagnostics Technology for Phase II SBIR
2. PRA International Rolls out Client Access to Oracle(R) RDC for Early Phase Studies
3. Treatment for chronic hepatitis C: A phase II study
4. New Pixantrone Phase III Data to be Presented at the 51st Annual Meeting of the American Society of Hematology
5. InstaMed Achieves Core Phase II Certification to Streamline Provider Access to Consistent Electronic Eligibility and Claim Status
6. Pharmacyclics, Inc. Announces Presentation of Interim Results From Phase I Trial of Its First-In-Human Btk Inhibitor PCI-32765
7. Aetna and WellPoint Achieve CORE Phase II Certification
8. Data from Phase 1 Study Confirm High Response Rate of Micromets Blinatumomab in Patients with Non-Hodgkins Lymphoma
9. Pharmacyclics, Inc. Reports Interim Safety and Clinical Data from a Phase I/II Clinical Trial of its Oral HDAC Inhibitor PCI-24781 in Lymphoma at the American Society of Hematology Annual Meeting
10. Hepregen Corporation Receives SBIR Phase II Grant from the National Science Foundation and Presents Corporate Update at OneMed Forum
11. Synomics Pharma and Bioscience Laboratories Announce Partnership to Provide Topical Clinical Phase 1 Study Services
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... The Rottenstein Law Group LLP, a New York-based nationwide ... Information Center at http://www.rotlaw.com/tylenol , dedicated to issues ... considering filing lawsuits. , The painkiller Tylenol (acetaminophen) ... according to a 2009 report from the U.S. Food ... FDA warned consumers against using more than the recommended ...
(Date:5/23/2013)... Washington, DC (PRWEB) May 23, 2013 ... have a great deal of control over their level ... their weight, yet far fewer are actually taking that ... International Food Information Council (IFIC) Foundation’s 2013 Food & ... of respondents say it’s possible to have “a great ...
(Date:5/23/2013)... IL (PRWEB) May 23, 2013 Jeanne ... fifth anniversary of its popular and only free OCD ... a successful continuing resource for OCD sufferers, the group ... OCD, and related disorders. This allows group participants ... and Exposure and Response Prevention. , “Participants in Beyond ...
(Date:5/23/2013)... May 23 (HealthDay News) -- Schools should ensure ... physical activity each day to support their health ... new report. Although previous studies show ... promotes health and development, it,s estimated that only ... meeting this recommendation, according to the report from ...
(Date:5/23/2013)... Reporter , , THURSDAY, May 23 (HealthDay News) -- Heavy ... as methamphetamine or crack cocaine, a new study contends. ... or ,coke mouth, it is startling to see the ... same," said Dr. Mohamed Bassiouny, a professor of restorative ... Philadelphia. Methamphetamine, crack cocaine and soda -- sweetened ...
Breaking Medicine News(10 mins):Health News:Rottenstein Law Group LLP Now Accepting Tylenol Cases, Announces New Tylenol Lawsuit Information Center 2Health News:Americans Experience “Control Gap” Regarding Their Weight, Diet, Activity Level; Rate Their Overall Diet a “B-Minus” 2Health News:Americans Experience “Control Gap” Regarding Their Weight, Diet, Activity Level; Rate Their Overall Diet a “B-Minus” 3Health News:Americans Experience “Control Gap” Regarding Their Weight, Diet, Activity Level; Rate Their Overall Diet a “B-Minus” 4Health News:Beyond OCD Support Group Marks Fifth Anniversary 2Health News:U.S. School Kids Should Get Hour of Exercise Daily: Report 2Health News:Diet Soda Habit as Bad for Teeth as Meth Addiction, Study Claims 2Health News:Diet Soda Habit as Bad for Teeth as Meth Addiction, Study Claims 3
... SHANGHAI, Sept. 10 /PRNewswire-Asia/ -- ... announced that Dr. Ge Li, the Company,s Chairman and ... Healthcare,Unplugged Conference in New York on Tuesday, September 15, ... present at the Bank of America Merrill,Lynch Global Healthcare ...
... 9 Family Research Council President Tony Perkins made the ... joint session of Congress. , , ... Tomorrow night in a live webcast at frcaction.org, ... Perkins will be joined by Senator Jim DeMint (R-SC), House ...
... , , MANASSAS, Va., Sept. 9 , ... of ConservativeHQ.com, regarding President Obama,s speech on health care legislation: ... far-left agenda by re-launching an effort for government-run health care. ... Obama is re-launching the conservative movement. , , ...
... , , , ... no meaningful health care reform , , ... Congress Wednesday evening, USAction President William McNary called on Congress to ... companies - and pass quality, affordable health care reform with a ...
... , OAKLAND, Calif., Sept. 9 ... "Technologies for Home and Community-Based Services: Considering the Options," at ... the City Center Marriott Hotel in Oakland on Friday, September 11, ... Lindeman, Ph.D.; Lynn Redington, Dr.PH., M.B.A.; and Valerie Steinmetz. They will ...
... action of nitrogen-containing bisphosphonate (N-BP) cancer drugs, used to ... bone metastasis, has been almost entirely unknown. Researchers writing ... have used ,barcoded, yeast mutants to identify new ... opening up opportunities for the development of new anticancer ...
Cached Medicine News:Health News:WuXi PharmaTech to Participate in Upcoming Investor Conferences 2Health News:President Obama's Campaign Style Speech Points to a Health Care Plan on Life Support 2Health News:Richard Viguerie: Obamacare is Restarting the Conservative Movement 2Health News:Technologies That Redefine Care for Older Americans to be Focus of Conference Session Led by Center for Technology and Aging 2
(Date:5/23/2013)... Conn. , May 23, 2013  CAS Medical Systems, ... medical devices for non-invasive patient monitoring, today announced that ... Officer,  will present at the 2 nd Annual Marcum ... Hyatt Hotel in New York City . ... p.m. ET in the Estate 10 room and will be ...
(Date:5/23/2013)... 2013 EarlySense, the market leader ... prize for ,Best Novel Idea, at the 8 th ... International Conference, hosted this year in the UK by ... clinical research team studying the impact of the EarlySense ... Los Angeles . The prize was awarded ...
(Date:5/23/2013)... 2013  Inhibikase Therapeutics, Inc., an emerging leader ... will present new results on its antiviral program ... by the PML Consortium (composed of Pfizer, Bristol-Meyers ... is the causative agent of Progressive Multifocal Leukoencephalopathy ... an extended release formulation, can clear JC polyomavirus ...
Breaking Medicine Technology:CASMED to Present at the 2nd Annual Marcum MicroCap Conference 2Clinical Team Researching the Impact of the EarlySense System Wins 'Best Novel Idea' Prize at the Rapid Response Systems and Medical Emergency Teams 2013 8th International Conference 2Clinical Team Researching the Impact of the EarlySense System Wins 'Best Novel Idea' Prize at the Rapid Response Systems and Medical Emergency Teams 2013 8th International Conference 3Clinical Team Researching the Impact of the EarlySense System Wins 'Best Novel Idea' Prize at the Rapid Response Systems and Medical Emergency Teams 2013 8th International Conference 4Inhibikase Therapeutics to present at Industry Conference on Drug-Induced Progressive Multifocal Leukoencephalopathy (PML) 2
... Dual EGFR / HER2 Tyrosine Kinase Inhibitor, Suggests Activity ... Mutations - (1,2)-The First Presentation of Data on BIBF ... Ingelheim will present new data on the company,s two ... the 2009 Annual Meeting of the American Society of ...
... TYRX, Inc., a leader in the ... the 30th Annual Scientific Sessions of the Heart ... its AIGISRX(TM) Antibacterial Envelope Retrospective Registry.AIGIS is an ... that help provide protection against infections associated with ...
Cached Medicine Technology:Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009 2Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009 3Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009 4Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009 5Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009 6Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009 7Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009 8Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009 9Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009 10TYRX Presents Early Clinical Results from AIGISRX(TM) Antibacterial Envelope Retrospective Registry 2TYRX Presents Early Clinical Results from AIGISRX(TM) Antibacterial Envelope Retrospective Registry 3TYRX Presents Early Clinical Results from AIGISRX(TM) Antibacterial Envelope Retrospective Registry 4TYRX Presents Early Clinical Results from AIGISRX(TM) Antibacterial Envelope Retrospective Registry 5TYRX Presents Early Clinical Results from AIGISRX(TM) Antibacterial Envelope Retrospective Registry 6
... The G-4 goniolaser lens features 4 precisely ... 360° view of the anterior chamber angle ... design (flanged glass contact element) provides a ... segment. 4 mirror lens provides ...
The Mid Field 30° lens has a bi-concave design to provide a wider field of view with a 30 degree offset image....
... The Chalam 45° Prism ... pathologies and are recommended for ... etc.) and Rhegmatogenus retinal detachment. ... panretinal photocoagulation and other midperipheral ...
... High-Mag 1.5x is specifically designed ... in macular hole surgery, optic ... membrane removal, traditional macular edema ... magnification. This lens was developed ...
Medicine Products: